APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripheral Neuritis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peripheral Neuritis Treatment Market Analysis and Forecast 2026-2032

20 December 2025199 pages

Choose your research edition.

Industry ResearchPeripheral Neuritis Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripheral Neuritis Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Peripheral Neuritis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripheral Neuritis Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripheral Neuritis Treatment Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Peripheral Neuritis Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Peripheral Neuritis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peripheral Neuritis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peripheral Neuritis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peripheral Neuritis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Peripheral Neuritis Treatment include Teva Pharmaceuticals, Sanofi, Johnson & Johnson, Novartis, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Biogen and Baxter Healthcare, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Peripheral Neuritis Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peripheral Neuritis Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Peripheral Neuritis Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peripheral Neuritis Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peripheral Neuritis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Peripheral Neuritis Treatment revenue, projected growth trends, production technology, application and end-user industry.

Peripheral Neuritis Treatment Segment by Company

Teva Pharmaceuticals

Sanofi

Johnson & Johnson

Novartis

Eli Lilly and Company

Pfizer

GlaxoSmithKline

Biogen

Baxter Healthcare

Depomed

Bristol-Myers Squibb

Peripheral Neuritis Treatment Segment by Type

Idiopathic Peripheral Neuropathy (IPN)

Diabetic Peripheral Neuropathy (DPN)

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Others

Peripheral Neuritis Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Peripheral Neuritis Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripheral Neuritis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripheral Neuritis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripheral Neuritis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Peripheral Neuritis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Peripheral Neuritis Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peripheral Neuritis Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peripheral Neuritis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Idiopathic Peripheral Neuropathy (IPN) Major Player Table 3. Diabetic Peripheral Neuropathy (DPN) Major Player Table 4. Chemotherapy-induced Peripheral Neuropathy (CIPN) Major Player Table 5. Others Major Player Table 6. Global Peripheral Neuritis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Pharmacies Major Player Table 8. Online Pharmacies Major Player Table 9. Retail Pharmacies Major Player Table 10. Peripheral Neuritis Treatment Industry Trends Table 11. Peripheral Neuritis Treatment Industry Drivers Table 12. Peripheral Neuritis Treatment Industry Opportunities and Challenges Table 13. Peripheral Neuritis Treatment Industry Restraints Table 14. Global Peripheral Neuritis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Peripheral Neuritis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Peripheral Neuritis Treatment Market Share by Region (2021-2026) Table 17. Global Peripheral Neuritis Treatment Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Peripheral Neuritis Treatment Market Share by Region (2027-2032) Table 19. Global Peripheral Neuritis Treatment Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Peripheral Neuritis Treatment Revenue Market Share by Players (2021-2026) Table 21. Global Peripheral Neuritis Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Peripheral Neuritis Treatment Key Players Headquarters & Area Served Table 23. Global Peripheral Neuritis Treatment Players, Product Type & Application Table 24. Global Peripheral Neuritis Treatment Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Peripheral Neuritis Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Peripheral Neuritis Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Peripheral Neuritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Peripheral Neuritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Peripheral Neuritis Treatment Revenue Market Share by Type (2021-2026) Table 31. Global Peripheral Neuritis Treatment Revenue Market Share by Type (2027-2032) Table 32. Global Peripheral Neuritis Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Peripheral Neuritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Peripheral Neuritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Peripheral Neuritis Treatment Revenue Market Share by Application (2021-2026) Table 36. Global Peripheral Neuritis Treatment Revenue Market Share by Application (2027-2032) Table 37. Teva Pharmaceuticals Company Information Table 38. Teva Pharmaceuticals Business Overview Table 39. Teva Pharmaceuticals Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Teva Pharmaceuticals Peripheral Neuritis Treatment Product Portfolio Table 41. Teva Pharmaceuticals Recent Development Table 42. Sanofi Company Information Table 43. Sanofi Business Overview Table 44. Sanofi Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Sanofi Peripheral Neuritis Treatment Product Portfolio Table 46. Sanofi Recent Development Table 47. Johnson & Johnson Company Information Table 48. Johnson & Johnson Business Overview Table 49. Johnson & Johnson Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Johnson & Johnson Peripheral Neuritis Treatment Product Portfolio Table 51. Johnson & Johnson Recent Development Table 52. Novartis Company Information Table 53. Novartis Business Overview Table 54. Novartis Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Novartis Peripheral Neuritis Treatment Product Portfolio Table 56. Novartis Recent Development Table 57. Eli Lilly and Company Company Information Table 58. Eli Lilly and Company Business Overview Table 59. Eli Lilly and Company Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Eli Lilly and Company Peripheral Neuritis Treatment Product Portfolio Table 61. Eli Lilly and Company Recent Development Table 62. Pfizer Company Information Table 63. Pfizer Business Overview Table 64. Pfizer Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Pfizer Peripheral Neuritis Treatment Product Portfolio Table 66. Pfizer Recent Development Table 67. GlaxoSmithKline Company Information Table 68. GlaxoSmithKline Business Overview Table 69. GlaxoSmithKline Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. GlaxoSmithKline Peripheral Neuritis Treatment Product Portfolio Table 71. GlaxoSmithKline Recent Development Table 72. Biogen Company Information Table 73. Biogen Business Overview Table 74. Biogen Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Biogen Peripheral Neuritis Treatment Product Portfolio Table 76. Biogen Recent Development Table 77. Baxter Healthcare Company Information Table 78. Baxter Healthcare Business Overview Table 79. Baxter Healthcare Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Baxter Healthcare Peripheral Neuritis Treatment Product Portfolio Table 81. Baxter Healthcare Recent Development Table 82. Depomed Company Information Table 83. Depomed Business Overview Table 84. Depomed Peripheral Neuritis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Depomed Peripheral Neuritis Treatment Product Portfolio Table 86. Depomed Recent Development Table 87. Bristol-Myers Squibb Company Information Table 88. Bristol-Myers Squibb Business Overview Table 89. Bristol-Myers Squibb Peripheral Neuritis Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Bristol-Myers Squibb Peripheral Neuritis Treatment Product Portfolio Table 91. Bristol-Myers Squibb Recent Development Table 92. North America Peripheral Neuritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 93. North America Peripheral Neuritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 94. North America Peripheral Neuritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 95. North America Peripheral Neuritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 96. North America Peripheral Neuritis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Peripheral Neuritis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 98. North America Peripheral Neuritis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 99. Europe Peripheral Neuritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe Peripheral Neuritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe Peripheral Neuritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe Peripheral Neuritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe Peripheral Neuritis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe Peripheral Neuritis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 105. Europe Peripheral Neuritis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 106. China Peripheral Neuritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 107. China Peripheral Neuritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 108. China Peripheral Neuritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 109. China Peripheral Neuritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Peripheral Neuritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 111. Asia Peripheral Neuritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 112. Asia Peripheral Neuritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 113. Asia Peripheral Neuritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Peripheral Neuritis Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia Peripheral Neuritis Treatment Revenue by Region (US$ Million) & (2021-2026) Table 116. Asia Peripheral Neuritis Treatment Revenue by Region (US$ Million) & (2027-2032) Table 117. SAMEA Peripheral Neuritis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 118. SAMEA Peripheral Neuritis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 119. SAMEA Peripheral Neuritis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 120. SAMEA Peripheral Neuritis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 121. SAMEA Peripheral Neuritis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. SAMEA Peripheral Neuritis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 123. SAMEA Peripheral Neuritis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Peripheral Neuritis Treatment Image Figure 2. Global Peripheral Neuritis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peripheral Neuritis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Idiopathic Peripheral Neuropathy (IPN) Image Figure 5. Diabetic Peripheral Neuropathy (DPN) Image Figure 6. Chemotherapy-induced Peripheral Neuropathy (CIPN) Image Figure 7. Others Image Figure 8. Global Peripheral Neuritis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Peripheral Neuritis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Pharmacies Image Figure 11. Online Pharmacies Image Figure 12. Retail Pharmacies Image Figure 13. Global Peripheral Neuritis Treatment Market Size (US$ Million) & (2021-2032) Figure 14. Global Peripheral Neuritis Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Peripheral Neuritis Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Peripheral Neuritis Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Peripheral Neuritis Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Peripheral Neuritis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Peripheral Neuritis Treatment Revenue Market Share by Type (2021-2032) Figure 21. Global Peripheral Neuritis Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Peripheral Neuritis Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Peripheral Neuritis Treatment Revenue Market Share by Application (2021-2032) Figure 24. North America Peripheral Neuritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Peripheral Neuritis Treatment Revenue Share by Type (2021-2032) Figure 26. North America Peripheral Neuritis Treatment Revenue Share by Application (2021-2032) Figure 27. North America Peripheral Neuritis Treatment Revenue Share by Country (2021-2032) Figure 28. United States Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Peripheral Neuritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Peripheral Neuritis Treatment Revenue Share by Type (2021-2032) Figure 33. Europe Peripheral Neuritis Treatment Revenue Share by Application (2021-2032) Figure 34. Europe Peripheral Neuritis Treatment Revenue Share by Country (2021-2032) Figure 35. Germany Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Peripheral Neuritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Peripheral Neuritis Treatment Revenue Share by Type (2021-2032) Figure 45. China Peripheral Neuritis Treatment Revenue Share by Application (2021-2032) Figure 46. Asia Peripheral Neuritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Peripheral Neuritis Treatment Revenue Share by Type (2021-2032) Figure 48. Asia Peripheral Neuritis Treatment Revenue Share by Application (2021-2032) Figure 49. Asia Peripheral Neuritis Treatment Revenue Share by Region (2021-2032) Figure 50. Japan Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Peripheral Neuritis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Peripheral Neuritis Treatment Revenue Share by Type (2021-2032) Figure 58. SAMEA Peripheral Neuritis Treatment Revenue Share by Application (2021-2032) Figure 59. SAMEA Peripheral Neuritis Treatment Revenue Share by Country (2021-2032) Figure 60. Brazil Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Peripheral Neuritis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Idiopathic Peripheral Neuropathy (IPN)
  • Diabetic Peripheral Neuropathy (DPN)
  • Chemotherapy-induced Peripheral Neuropathy (CIPN)
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Teva Pharmaceuticals
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Baxter Healthcare
  • Depomed
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peripheral Neuritis Treatment Market by Type
  3. 1.2.1 Global Peripheral Neuritis Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Idiopathic Peripheral Neuropathy (IPN)
  5. 1.2.3 Diabetic Peripheral Neuropathy (DPN)
  6. 1.2.4 Chemotherapy-induced Peripheral Neuropathy (CIPN)
  7. 1.2.5 Others
  8. 1.3 Peripheral Neuritis Treatment Market by Application
  9. 1.3.1 Global Peripheral Neuritis Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacies
  11. 1.3.3 Online Pharmacies
  12. 1.3.4 Retail Pharmacies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Peripheral Neuritis Treatment Market Dynamics
  1. 2.1 Peripheral Neuritis Treatment Industry Trends
  2. 2.2 Peripheral Neuritis Treatment Industry Drivers
  3. 2.3 Peripheral Neuritis Treatment Industry Opportunities and Challenges
  4. 2.4 Peripheral Neuritis Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Peripheral Neuritis Treatment Market Perspective (2021-2032)
  2. 3.2 Global Peripheral Neuritis Treatment Growth Trends by Region
  3. 3.2.1 Global Peripheral Neuritis Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peripheral Neuritis Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Peripheral Neuritis Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Peripheral Neuritis Treatment Revenue by Players
  2. 4.1.1 Global Peripheral Neuritis Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Peripheral Neuritis Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Peripheral Neuritis Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peripheral Neuritis Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Peripheral Neuritis Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Peripheral Neuritis Treatment Players, Product Type & Application
  8. 4.5 Global Peripheral Neuritis Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Peripheral Neuritis Treatment Market CR5 and HHI
  11. 4.6.3 2025 Peripheral Neuritis Treatment Tier 1, Tier 2, and Tier 3
5 Peripheral Neuritis Treatment Market Size by Type
  1. 5.1 Global Peripheral Neuritis Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Peripheral Neuritis Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Peripheral Neuritis Treatment Revenue Market Share by Type (2021-2032)
6 Peripheral Neuritis Treatment Market Size by Application
  1. 6.1 Global Peripheral Neuritis Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Peripheral Neuritis Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Peripheral Neuritis Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceuticals
  2. 7.1.1 Teva Pharmaceuticals Company Information
  3. 7.1.2 Teva Pharmaceuticals Business Overview
  4. 7.1.3 Teva Pharmaceuticals Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceuticals Peripheral Neuritis Treatment Product Portfolio
  6. 7.1.5 Teva Pharmaceuticals Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Peripheral Neuritis Treatment Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Johnson & Johnson
  14. 7.3.1 Johnson & Johnson Company Information
  15. 7.3.2 Johnson & Johnson Business Overview
  16. 7.3.3 Johnson & Johnson Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Johnson & Johnson Peripheral Neuritis Treatment Product Portfolio
  18. 7.3.5 Johnson & Johnson Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Peripheral Neuritis Treatment Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Eli Lilly and Company
  26. 7.5.1 Eli Lilly and Company Company Information
  27. 7.5.2 Eli Lilly and Company Business Overview
  28. 7.5.3 Eli Lilly and Company Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly and Company Peripheral Neuritis Treatment Product Portfolio
  30. 7.5.5 Eli Lilly and Company Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Peripheral Neuritis Treatment Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 GlaxoSmithKline
  38. 7.7.1 GlaxoSmithKline Company Information
  39. 7.7.2 GlaxoSmithKline Business Overview
  40. 7.7.3 GlaxoSmithKline Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GlaxoSmithKline Peripheral Neuritis Treatment Product Portfolio
  42. 7.7.5 GlaxoSmithKline Recent Developments
  43. 7.8 Biogen
  44. 7.8.1 Biogen Company Information
  45. 7.8.2 Biogen Business Overview
  46. 7.8.3 Biogen Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biogen Peripheral Neuritis Treatment Product Portfolio
  48. 7.8.5 Biogen Recent Developments
  49. 7.9 Baxter Healthcare
  50. 7.9.1 Baxter Healthcare Company Information
  51. 7.9.2 Baxter Healthcare Business Overview
  52. 7.9.3 Baxter Healthcare Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Baxter Healthcare Peripheral Neuritis Treatment Product Portfolio
  54. 7.9.5 Baxter Healthcare Recent Developments
  55. 7.10 Depomed
  56. 7.10.1 Depomed Company Information
  57. 7.10.2 Depomed Business Overview
  58. 7.10.3 Depomed Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Depomed Peripheral Neuritis Treatment Product Portfolio
  60. 7.10.5 Depomed Recent Developments
  61. 7.11 Bristol-Myers Squibb
  62. 7.11.1 Bristol-Myers Squibb Company Information
  63. 7.11.2 Bristol-Myers Squibb Business Overview
  64. 7.11.3 Bristol-Myers Squibb Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bristol-Myers Squibb Peripheral Neuritis Treatment Product Portfolio
  66. 7.11.5 Bristol-Myers Squibb Recent Developments
8 North America
  1. 8.1 North America Peripheral Neuritis Treatment Revenue (2021-2032)
  2. 8.2 North America Peripheral Neuritis Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Peripheral Neuritis Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Peripheral Neuritis Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Peripheral Neuritis Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Peripheral Neuritis Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Peripheral Neuritis Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Peripheral Neuritis Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Peripheral Neuritis Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Peripheral Neuritis Treatment Revenue by Country
  11. 8.6.1 North America Peripheral Neuritis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Peripheral Neuritis Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Peripheral Neuritis Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Peripheral Neuritis Treatment Revenue (2021-2032)
  2. 9.2 Europe Peripheral Neuritis Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Peripheral Neuritis Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Peripheral Neuritis Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Peripheral Neuritis Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Peripheral Neuritis Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Peripheral Neuritis Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Peripheral Neuritis Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Peripheral Neuritis Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Peripheral Neuritis Treatment Revenue by Country
  11. 9.6.1 Europe Peripheral Neuritis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Peripheral Neuritis Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Peripheral Neuritis Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Peripheral Neuritis Treatment Revenue (2021-2032)
  2. 10.2 China Peripheral Neuritis Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Peripheral Neuritis Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Peripheral Neuritis Treatment Revenue by Type (2027-2032)
  5. 10.3 China Peripheral Neuritis Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Peripheral Neuritis Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Peripheral Neuritis Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Peripheral Neuritis Treatment Revenue by Application (2027-2032)
  9. 10.5 China Peripheral Neuritis Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peripheral Neuritis Treatment Revenue (2021-2032)
  2. 11.2 Asia Peripheral Neuritis Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Peripheral Neuritis Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Peripheral Neuritis Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Peripheral Neuritis Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Peripheral Neuritis Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Peripheral Neuritis Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Peripheral Neuritis Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Peripheral Neuritis Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Peripheral Neuritis Treatment Revenue by Country
  11. 11.6.1 Asia Peripheral Neuritis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Peripheral Neuritis Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Peripheral Neuritis Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peripheral Neuritis Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Peripheral Neuritis Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Peripheral Neuritis Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Peripheral Neuritis Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Peripheral Neuritis Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Peripheral Neuritis Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Peripheral Neuritis Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Peripheral Neuritis Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Peripheral Neuritis Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Peripheral Neuritis Treatment Revenue by Country
  11. 12.6.1 SAMEA Peripheral Neuritis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Peripheral Neuritis Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Peripheral Neuritis Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst